Kangpu Biopharmaceuticals, Ltd.

Chinese developers of advanced therapeutics, including cell and gene therapies, have continued to garner support from venture capital and private equity investors in the past weeks. Shanghai-based Epi

Zydus Lifesciences Limited expects to begin chipping away at Bristol Myers Squibb Company ’s Revlimid (lenalidomide) franchise in the US, the latter’s best-selling immunomodulatory drug, in the near

Zydus Lifesciences Limited expects to begin chipping away at Bristol Myers Squibb Company ’ Revlimid (lenalidomide) franchise in the US, the latter’s best-selling immunomodulatory drug, in the near

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big